A range of different immunotherapies such as PD-1/PD-L1 checkpoint inhibitors, chimeric antigen receptor-T cells (CAR-T) and adoptive T cell strategies have currently been actively investigated in patients with gliomas [4,5,6]. This evidence concerns the gene PDCD1 and central nervous system cancer.